Cabozantinib Production Cost Reports

The report provides a detailed analysis essential for establishing a cabozantinib production plant. It encompasses all critical aspects necessary for cabozantinib production, including the cost of cabozantinib production, cabozantinib plant cost, cabozantinib production costs, and the overall cabozantinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a cabozantinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Cabozantinib is a targeted anti-cancer medicine that is mainly used for the treatment of advanced or metastatic cancers. It is primarily used in the treatment of certain types of cancer, including kidney cancer, liver cancer, and thyroid cancer. It works by blocking specific proteins that help cancer cells grow and spread in the body. The compound potently inhibits several receptor tyrosine kinases, including VEGFR2, c-Met, AXL, RET, KIT, and FLT3, thereby disrupting tumour cell proliferation, vascular density, and metastatic signalling. It is commonly used as an oral medicine for the treatment of kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma), and thyroid cancer. It is usually taken as an oral tablet, especially when the disease has spread or stopped responding to other treatments. It is also used in clinical oncology to slow tumour progression and improve patient outcomes. In addition, it plays an important role in cancer research and drug development for studying tumour growth control.

The demand for cabozantinib is predominantly driven by its application as an antineoplastic agent in cancer treatment and related therapeutic research, which boosts its market growth. Its application as an oral anti-cancer medicine for the treatment of advanced, metastatic medullary thyroid cancer and refractory renal cell carcinoma also fuels its demand in the pharmaceutical industry. Its application as a targeted cancer therapy for the treatment of hepatocellular carcinoma in previously treated patients further boosts its demand in the medical and pharmaceutical industries.

Its usage as an antineoplastic agent in research studies and clinical trials for its possible use in treating other solid tumours also drives its demand in the medical research sector. Its effectiveness in slowing tumour growth and improving patient outcomes has increased its adoption in oncology treatment protocols across hospitals and speciality cancer centres. Industrial cabozantinib procurement is influenced by several factors, including the availability and cost of active pharmaceutical ingredients, strict regulatory approvals, and compliance with quality and safety standards. Moreover, ongoing research in cancer therapies, increasing investments in oncology drug development, reliable supplier networks, and advancements in drug production processes play an important role in shaping its overall market trends.

Raw Material for Cabozantinib Production

According to the cabozantinib production plant project report, the major raw materials for cabozantinib production include 6,7-dimethoxy-quinoline-4-ol, phosphoryl chloride, 4-aminophenol, diacid, p-fluoroaniline, oxalyl chloride, and (S)-malic acid.

Production Process of Cabozantinib

The extensive cabozantinib production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of cabozantinib malate begins with 6,7-dimethoxy-quinoline-4-ol, which is treated with phosphoryl chloride. (POCl3) to form a chlorinated intermediate. Then, this compound is reacted with 4-aminophenol under basic conditions to produce a diaryl ether intermediate containing the aniline group. The resulting aniline derivative is coupled with an amidoacid chloride, prepared through a sequence involving activation of a diacid, reaction with p-fluoroaniline, and conversion to an acid chloride using oxalyl chloride. This coupling forms cabozantinib as a free base, which is then converted into its final form by reacting with (S)-malic acid to produce cabozantinib (S)-malate.

Cabozantinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that appears as a white to beige crystalline powder. It exerts its antitumor effect by inhibiting the main kinases involved in tumour growth, angiogenesis, and metastasis. The molecular formula of the compound is C28H24FN3O5, and its molar mass is 501.51 g/mol. It has a density of approximately 1.396 g/cm³, and its boiling point is approximately 758.1 °C. It is generally insoluble in water but is soluble in dimethyl sulfoxide (DMSO). It has a melting point of around 212-215 °C. Common adverse effects associated with the compound include diarrhoea, stomatitis, palmar-plantar erythrodysesthesia, weight loss, nausea, fatigue, and hypertension. It is recommended to use this compound strictly under medical supervision, and pregnant women should avoid taking the drug as it may cause harm to the fetus.